Towards defining the genetic framework for clinical response to treatment with BYL719, a PI3Kalpha-specific inhibitor.

被引：1

作者：

Rodon, Jordi ^{[1
]}

Juric, Dejan ^{[2
]}

Gonzalez-Angulo, Ana-Maria ^{[3
]}

Bendell, Johanna ^{[4
]}

Berlin, Jordan ^{[5
]}

Bootle, Douglas ^{[6
]}

Gravelin, Kathlene ^{[7
]}

Huang, Alan ^{[7
]}

Derti, Adnan ^{[7
]}

Lehar, Joseph ^{[7
]}

Wuerthner, Jens ^{[6
]}

Boehm, Markus ^{[6
]}

van Allen, Eliezer ^{[8
]}

Wagle, Nikhil ^{[8
]}

Garraway, Levi A. ^{[8
]}

Yelensky, Roman ^{[9
]}

Stephens, Philip J. ^{[9
]}

Miller, Vincent A. ^{[9
]}

Schlegel, Robert ^{[7
]}

Quadt, Cornelia ^{[6
]}

Baselga, Jose ^{[10
]}

机构：

[1] Vail dHebron Univ Hosp, Dept Med Oncol, Barcelona, Spain

[2] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA

[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[4] Sarah Cannon Res Inst, Nashville, TN USA

[5] Vanderbilt Canc Ctr, Nashville, TN USA

[6] Novartis Pharma AG, Oncol Translat Med, Basel, Switzerland

[7] NIBR Inc, Oncol Translat Med, Cambridge, MA USA

[8] Broad Inst, Cambridge, MA USA

[9] Fdn Med Inc, Cambridge, MA USA

[10] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

来源：

CANCER RESEARCH | 2013年 / 73卷 / 08期

关键词：

D O I：

10.1158/1538-7445.AM2013-LB-65

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LB65

引用

页数：2

共 44 条

[31] Phase I study of the alpha specific PI3-Kinase inhibitor BYL719 and the poly (ADP-Ribose) polymerase (PARP) inhibitor olaparib in recurrent ovarian and breast cancer: Analysis of the dose escalation and ovarian cancer expansion cohort
Konstantinopoulos, Panagiotis A.
Barry, William T.
Birrer, Michael
Westin, Shannon N.
Farooq, Sarah
Cadoo, Karen
Whalen, Christin
Luo, Weixiu
Liu, Hui
Aghajanian, Carol
Solit, David B.
Mills, Gordon B.
Taylor, Barry S.
Won, Helen
Berger, Michael F.
Palakurthi, Sangeetha
Liu, Joyce F.
Cantley, Lew
Kaufmann, Scott H.
Swisher, Elizabeth M.
D'Andrea, Alan D.
Winer, Eric
Wulf, Gerburg M.
Matulonis, Ursula A.
CANCER RESEARCH, 2017, 77
[32] Targeting PIK3CA mutant breast cancer with the combination of PIK3CA-specific inhibitor, BYL719, and IGF1-R antibody, ganitumab.
Cao, Z. Alexander
Pinzon-Ortiz, Maria
Chen, Yan
Li, Xiaoyan
Beltran, Pedro J.
Gansert, Jennifer L.
Peters, Malte
Schlegel, Robert
Schumacher, Karl Maria
Huang, Alan
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[33] PI3Kα-specific inhibitor BYL-719 synergizes with cisplatin in vitro in PIK3CA-mutated ovarian cancer cells
Thibault, Benoit
Thole, Adrien
D'Angelo, Romina
Basset, Celine
Guillermet-Guibert, Julie
SCIENTIFIC REPORTS, 2025, 15 (01):
[34] Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the a-specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF mutant colorectal cancer
Tabernero, J.
van Geel, R.
Bendell, J. C.
Spreafico, A.
Schuler, M.
Yoshino, T.
Delord, J. P.
Yamada, Y.
Lolkema, M. P.
Fans, J. E.
Eskens, F. A. L. M.
Sharma, S.
Yaeger, R.
Lenz, H. J.
Wainberg, Z.
Avsar, E.
Chatterjee, A.
Jaeger, S.
Demuth, T.
Schellens, J. H. M.
EUROPEAN JOURNAL OF CANCER, 2014, 50 : 199 - 199
[35] SU2C phase Ib study of the PI3Kα inhibitor BYL719 with letrozole in ER+/HER2-metastatic breast cancer (MBC).
Mayer, Ingrid A.
Abramson, Vandana Gupta
Balko, Justin M.
Sanders, Melinda
Juric, Dejan
Li, Yisheng
Ley, Lewis Cant
Winer, Eric P.
Arteag, Carlos L.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[36] Phase I study of the selective BRAFV600inhibitor encorafenib (LGX818) combined with cetuximab and with or without the α-specific PI3K inhibitor BYL719 in patients with advanced BRAF-mutant colorectal cancer.
Van Geel, Robin
Elez, Elena
Bendell, Johanna C.
Faris, Jason Edward
Lolkema, Martijn P. J. K.
Eskens, Ferry
Spreafico, Anna
Kavan, Petr
Delord, Jean-Pierre
Schuler, Martin H.
Wainberg, Zev A.
Yamada, Yasuhide
Yoshino, Takayuki
Demuth, Tim
Avsar, Emin
Chatterjee, Arkendu
Zhu, Peijuan
Bernards, Rene
Tabernero, Josep
Schellens, Jan H. M.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[37] SU2C Phase Ib study of the PI3K-alpha inhibitor BYL719 (alpelisib) with letrozole in ER+/HER2-metastatic breast cancer
Mayer, Ingrid A.
Abramson, Vandana
Balko, Justin
Sanders, Melinda
Juric, Dejan
Solit, David
Li, Yisheng
Cantley, Lewis
Winer, Eric
Arteaga, Carlos
CANCER RESEARCH, 2015, 75
[38] Effects of PI3kα inhibitor BYL719 on overcoming everolimus resistance and inducing re-expression of somatostatin receptors in an everolimus-resistant orthotopic pancreatic NET xenograft mouse model
Mohan, A.
Prasad, S.
Schmitz-Peiffer, F.
Lange, C.
Lukas, M.
Koziolek, E. J.
Pacak, K.
Ilmer, M.
Grossman, A.
Wang, K.
Reul, A.
Maurer, J.
Schober, L.
Friemel, J.
Reincke, M.
Auernhammer, C. J.
Beuschlein, F.
Brenner, W.
Nolting, S.
Beindorff, N.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S329 - S329
[39] Plasma and tumor genomic correlates of response to BYL719 in PI3KCA mutated metastatic ER-positive breast cancer (ER+/HER2-BC).
Dawson, Sarah-Jane
Wein, Lironne
Silva, Maria Joao
Luen, Stephen James
VanGeelen, Courtney
Moodie, Kate
Savas, Peter
Weng, Chen-Fang
Bujak, Andjelija Zivanovic
Yeung, Miriam M.
Ftouni, Sarah
Kuykhoven, Keilly
Hicks, Rodney J.
Francis, Prudence A.
Lee, Chee Khoon
Loi, Sherene
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[40] Final biomarker analysis of the phase I study of the selective BRAF V600 inhibitor encorafenib (LGX818) combined with cetuximab with or without the α-specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF-mutant colorectal cancer
Schellens, Jan H. M.
van Geel, Robin
Bendell, Johanna C.
Spreafico, Anna
Schuler, Martin
Yoshino, Takayuki
Delord, Jean-Pierre
Yamada, Yasuhide
Lolkema, Martijn P.
Faris, Jason E.
Eskens, Ferry A. L. M.
Sharma, Sunil
Yaeqer, Rona
Lenz, Heinz-Josef
Wainberg, Zev A.
Avsar, Emin
Chatterjee, Arkendu
Jaeger, Savina
Demuth, Tim
Tabemero, Josep
CANCER RESEARCH, 2015, 75

← 1 2 3 4 5 →